Save this technology
Save to Existing Project
Save to a New Project
Phase II (ready) Phospholipid to Treat MS and Other Autoimmunities
GRI Bio, Inc United States flag United States
Abstract ID:
Phospholipid type II NKT agonist to treat MS and other autoimmune conditions. Ready for phase II. Excellent data in in-vivo models of MS
Contact Sean Edwards
GRI Bio is a drug development company focused on treating inflammatory diseases. We have a proprietary technology platform based on research out of University of California at San Diego that includes a portfolio of small molecule drugs and phospholipids that have demonstrated the ability to inhibit inflammatory immune responses by modulating type I and type II NKT cells. Our therapeutic areas of focus are liver disease and auto-immunity.

GRI-0124 is an orally delivered phospholipid that has an established safety profile. The ability of the drug to stimulate type II NKT cells has shown significant reductions in autoimmune inflammatory responses. The drug has all required safety data to begin a phase II trial. In-vivo models of MS have shown impressive improvements in the disease.

We have a library of over 1000 NCE compounds with similar MOA. Two of these candidates are phase I ready and could be targeted for MS or other autoimmune conditions such as IBD, Chron's disease or rheumatoid arthritis.
Last Updated Feb 2017
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS

Opportunity Contact